Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor

Researchers comparing post-transplant cyclophosphamide (PTCY) versus anti-thymocyte globulin (ATG) in adult patients with lymphoproliferative disease undergoing a first 9/10 mismatch unrelated donor hematopoietic stem cell transplantation with a reduced intensity conditioning regimen found no differences in relapse incidence, non-relapse mortality, progression-free survival, overall survival, or GVHD-relapse-free survival at 1 year between the two arms. The cumulative incidence of 1-year extensive chronic GVHD was 18% in the ATG and 5% in the PTCY group, respectively (p = .06).